The meeting of the German Society of Human Genetics (gfh) was held in Weimar, Germany this week and of course the attendees had the opportunity to visit the joined booth of MetaSystems and MetaSystems Probes. Main topics of the exhibition have been the latest advancements of the Neon case and imaging platform and RapidHyb, the revolutionary fast hybridization times of MetaSystems Probes' FISH probes.
XL t(11;14) MYEOV/IGH DF
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl (10 Tests)
The mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with an aggressive clinical course. It is genetically characterized by t(11;14)(q13;q32) and is present in about 95% of MCL patients. By lower frequency, t(11;14) is also detectable in B-cell prolymphocytic leukemia, myelomas and chronic lymphocytic leukemia. The translocation induces overexpression of CCND1 which is normally not detected in B lymphocytes. CCND1 is a major player in cell cycle regulation and involved in the G1/S-phase transition. The oncogenic potential of CCND1 overexpression is related to its role in the cell cycle but also to other, non-cell cycle-related mechanisms as increased genomic instability and cell survival. t(11;14) is considered as a primary event, often followed by secondary chromosome alterations.
In multiple myeloma (MM), t(11;14) is the most common translocation, detectable in about 15-20% of all MM patients by FISH. Conventional cytogenetics has a much lower sensitivity, detecting t(11;14) in about 5% of MM patients. MM t(11;14) patients do have a relatively favorable outcome compared to other recurrent IGH translocations.
- Non-Hodgkin Lymphomas (NHL)
- Multiple Myeloma and Plasma Cell Neoplasms (MM)
- Chronic Lymphocytic Leukemia (CLL)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.
- Fonesca et al (2002) Blood 99:3735-3741
- Bentz et al (2004) Canc Cytopath 102:124-131
- Jares et al (2012) J Clin Invest 122:3416-3423